Arcus Biosciences (RCUS) Projected to Post Quarterly Earnings on Wednesday

Arcus Biosciences (NYSE:RCUS) is expected to be releasing its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect Arcus Biosciences to announce earnings of ($0.8908) per share and revenue of $7.58 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:05 PM ET.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.72) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.17. Arcus Biosciences had a negative return on equity of 89.54% and a negative net margin of 393.16%. The firm had revenue of $41.00 million during the quarter, compared to analysts’ expectations of $21.98 million. The business’s quarterly revenue was down 74.4% on a year-over-year basis. On average, analysts expect Arcus Biosciences to post ($3.55) EPS for the current fiscal year and ($3.12) EPS for the next fiscal year.

Arcus Biosciences Stock Performance

Shares of Arcus Biosciences stock opened at $17.81 on Tuesday. Arcus Biosciences has a one year low of $17.43 and a one year high of $31.74. The company has a market cap of $2.27 billion, a price-to-earnings ratio of -4.57 and a beta of 0.94. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.82 and a current ratio of 3.82. The business’s 50 day moving average price is $24.73 and its 200 day moving average price is $24.62.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Wells Fargo & Company raised their target price on Arcus Biosciences from $23.00 to $26.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 6th. HC Wainwright boosted their price target on shares of Arcus Biosciences from $32.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, July 20th. The Goldman Sachs Group reissued a “buy” rating and issued a $42.00 price objective on shares of Arcus Biosciences in a report on Friday, August 7th. TD Cowen began coverage on shares of Arcus Biosciences in a research report on Wednesday, September 16th. They set a “buy” rating for the company. Finally, Citigroup lifted their target price on shares of Arcus Biosciences from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Wednesday, October 21st. Twelve equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $39.64.

Insiders Place Their Bets

In related news, CAO Alexander Azoy sold 2,827 shares of the stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $30.00, for a total value of $84,810.00. Following the completion of the transaction, the chief accounting officer directly owned 39,581 shares in the company, valued at approximately $1,187,430. This represents a 6.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 7.60% of the company’s stock.

About Arcus Biosciences

Arcus Biosciences, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases. The company uses its research platform to discover and advance medicines designed to target immune suppression and other biological mechanisms involved in tumor growth.

Arcus’s oncology pipeline has included antibody-based and small-molecule therapies aimed at targets such as TIGIT, PD-1, CD73, and the adenosine A2A and A2B receptors. Its key development programs have included domvanalimab, zimberelimab, quemliclustat, and etrumadenant, which have been evaluated in clinical studies across several cancer types, including lung, gastrointestinal, and colorectal cancers.

Founded in 2015 and headquartered in Hayward, California, Arcus conducts research and clinical-development activities intended to support potential commercialization in international markets.